Clinical Trial

A Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HRS-9821 Powder for Inhalation Administered as a Single Dose in Healthy Participants and Multiple Doses in Patients With COPD

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The aim of this study was to evaluate the safety and tolerability of HRS-9821 Powder for Inhalation administered in a single dose in healthy individuals and multiple doses in patients with COPD。
Protocol Amendment History 1 change
critical Recruitment opened 2026-07-21
Trial Details
NCT Number NCT07567872
Lead Sponsor Guangdong Hengrui Pharmaceutical Co., Ltd
Conditions COPD
Enrollment 48 participants
Start Date 2026-07-09
Primary Completion 2026-09 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2026-07-20